Search

everythinglearnresearchcommunity

for

Search:↓

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

Topical finasteride can reduce scalp DHT as effectively as oral finasteride with fewer systemic effects, but availability is limited. Some users make their own solutions due to limited access.

A user shared their 4-month progress using 0.25 mg finasteride daily for hair loss, reporting significant improvement and minimal side effects. Other users discussed their experiences with different dosages and side effects.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.

A user has been using finasteride for 3 years with good results but wants to switch to dutasteride due to a plateau. They are seeking an online pharmacy that delivers dutasteride to Europe.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Dutasteride is shown to be significantly more effective than finasteride for treating male androgenic alopecia. Users discuss the difficulty of obtaining dutasteride in some countries and share personal experiences with its effectiveness and side effects.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The conversation is about someone's 4-month hair regrowth progress using 0.5mg dutasteride and topical minoxidil. Another person is inspired and is using 5mg finasteride and 5% minoxidil topically twice daily, hoping for similar results.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The conclusion of the conversation is that the user experienced noticeable regrowth of hair after using dutasteride as a single treatment for about 1.5 years. No before photos were available.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

Finasteride users have mixed experiences with creatine; some experience increased hair loss, while others do not. Finasteride's DHT-blocking effects might counteract any DHT increase from creatine, but individual responses vary.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

The user shared progress pictures after 4 months of using 1.25 mg oral Finasteride every other day. Responses indicate hair regrowth and a filling hairline, with one user asking about side effects or shedding.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.